Clopidogrel and ASA after CABG for NSTEMI
|
|
- Rolf Campbell
- 6 years ago
- Views:
Transcription
1 Clopidogrel and ASA after CABG for NSTEMI May 17, 2007 Justin Lee Pharmacy Resident University Health Network
2 Objectives At the end of this session, you should be able to: Explain the rationale for antiplatelet therapy post- NSTEMI and post-cabg Discuss the potential benefits and risks of combination therapy (clopidogrel( and ASA) Synthesize the current evidence and make an appropriate treatment recommendations on a patient- per-patient patient basis
3 Patient Case
4 Mr. R 59 yo caucasian male Reason for Admission Retrosternal chest pain radiating to the neck Partially responsive to medical therapy ECG suggestive of ischemia without ST elevation Tn = CK = 1111 Diagnosis = NSTEMI
5 Past Medical History Coronary artery disease (CAD) RCA dissection (Aug 2002) Recurrent re-stenosis (Jan 2003, Aug 2003) NSTEMI (Feb 2007) Multiple PCI to LAD, LCx,, RCA 21 stents!!! Drug-eluting stent (Feb 2007) Peripheral vascular disease (PVD) Bilateral femoral popliteal bypass R carotid endartectomy,, residual left carotid stenosis Hypertension Dyslipidemia
6 Best Possible Medication History Indication CAD HTN Intermittent Claudication Medication EC ASA 325 mg po OD Clopidogrel 75 mg po OD Atenolol 50 mg po BID Ramipril 2.5 mg po OD Amlodipine 5 mg po OD Rosuvastatin 10 mg po OD Folic acid 5 mg po OD Nitroglycerin 0.4 mg Spray SL PRN Pentoxyfylline SR 400 mg po TID Cellulitis Cephalexein 500 mg po TID
7 HPI April 12, 2007 Sault Ste. Marie Hospital R leg - swelling and redness Fever and chills Rx Cephalexein x 10 d for R leg cellulitis April 20, 2007 Sault Ste. Marie Hospital Retrosternal chest pain radiating to the neck Rx Heparin, NTG, morphine Transfer to TGH due to residual chest pain
8 HPI April 20, 2007 TGH CCU Rx Eptifibatide Cath Lab Angiogram 80% stenosis LAD/Cx 70% stenosis LAD 100% stenosis RCA April 24, 2007 Clopidogrel continued until the time of operation CABG x 3
9 Angiogram Report
10 Medication in Hospital - Pre-CABG Indication CAD NSTEMI Medication UFH IV infusion NTG IV infusion Eptifibatide IV infusion EC ASA 325 mg po OD Clopidogrel 75 mg po OD Atenolol 50 mg po BID Rosuvastatin 10 mg po OD Folic acid 5 mg po OD Intermittent Claudication Ramipril 2.5 mg po OD - HOLD Amlodipine 5 mg po OD - HOLD Pentoxyfylline SR 400 mg po TID
11 Clinical Question Does the benefit of continuing the combination of clopidogrel 75 mg po OD and ASA mg po OD outweigh the risks post-operatively operatively after CABG for NSTEMI?
12 What would you do? A) Start ASA alone 48 h post op B) Start ASA alone 10 d post op C) Start ASA + Clopidogrel 48 h post-op op D) Start ASA + Clopidogrel 10 d post-op op
13 NSTEMI, Graft Disease, Stent Thrombosis Why is the rationale for antiplatelet therapy?
14 NSTEMI Plaque rupture or erosion initiates cascade: Platelet activation Thrombosis Fibrin clot formation Fibrinolysis (exogenous or endogenous) paradoxically can lead to re-thrombosis Increase in thrombin generation Increase in platelet aggregation
15 Stent Thrombosis Bare surface of stents induce platelet adhesion, activation and thrombus formation Stents are gradually covered with endothelial cells that do not induce thrombus formation When process of endothelial growth is complete, there is decreased need for platelet inhibition
16 Stent Thrombosis Drug-eluting stents prevent re-stenosis release anti-proliferative drugs inhibit neointimal thickening of smooth muscle prevent healing growth of endothelial cells on stent surface stent struts remains exposed blood continues to flow over "bare" surface for prolonged period of time
17 Graft Disease Saphenous venous graft (SVG) disease is clinically significant problem involving: Thrombosis Intimal hyperplasia Atherosclerosis High risk for subsequent ischemic events (death, MI, stroke) Curr Control Trials Cardiovasc Med 2005; 6: 15
18 Within 1 year, Graft Disease 15% of grafts will occlude Within 10 years, 60% of grafts are patent 50% of these grafts are free of significant stenosis Curr Control Trials Cardiovasc Med 2005; 6: 15
19 Antiplatelet Therapy for NSTEMI and CABG
20 Background Knowledge about antiplatelet therapy post- CABG is currently limited Evidence is primarily derived from myocardial infarction or angina pectoris trials Can we extrapolate this information to patients post-operatively operatively for patients who have undergone CABG for NSTEMI?
21 2002 ACC/AHA UA/NSTEMI Guidelines Clopidogrel should be added to ASA as soon as possible on admission and administered for at least 1 month and up to 9 months Medical treatment for post-cabg patients should follow the same guidelines as for non post post-cabg patients with UA/NSTEMI
22 2004 ACC/AHA CABG Guidelines ASA mg/d should be initiated within 48 h after CABG and continued indefinitely Protects against early graft closure Reduces subsequent mortality, MI, stroke Clopidogrel is alternative for ASA allergic patients No info on clopidogrel and ASA combination ACC/AHA 2004 Guideline Update for CABG
23 2004 CHEST Antithrombotic Therapy for CABG Guidelines ASA mg/d should be initiated 6 h after CABG and continued indefinitely Clopidogrel 300 mg followed by 75 mg/d is alternative for ASA allergic patients CHEST 2004; 126: 600S-608S
24 2004 CHEST Antithrombotic Therapy for CABG Guidelines Patients who undergo CABG for NSTEMI, Clopidogrel 75 mg x months in addition to treatment with aspirin Grade 1A Recommendation Rationale for recommendation High value on avoiding myocardial infarction Low value on avoiding bleeding complications CHEST 2004; 126: 600S-608S
25 Grade 1A Recommendation Strong recommendation Can apply to most patients in most circumstances without reservation Based on randomized controlled trials (RCTs) without important limitations Benefits / Risks are clear
26 What is the evidence? No RCTs to date formally test the hypothesis of dual antiplatelet therapy post-operatively operatively after CABG
27 CURE N Eng J Med 2001; 345:
28 Multi-national Multi-center Prospective Randomized Double-blinded blinded Placebo-controlled controlled Parallel-group Superiority trial CURE Trial
29 Study Design Patients with Acute Coronary Syndrome (unstable angina or non-st-segment elevation MI) Clopidogrel 300 mg loading dose R 3 m. Visit 6 m. Visit 9 m. Visit 12 m. or Final Visit Clopidogrel 75mg q.d. + ASA mg q.d.* (6259 patients) 3 months double-blind treatment 12 months Placebo + ASA mg q.d.* (6303 patients) R = Randomization * In combination with other standard therapy The CURE Trial Investigators. N Engl J Med. 2001;345: Day 1 Placebo loading dose Discharge Visit 1 m. Visit
30 Primary outcomes CURE Trial CV death / nonfatal MI / stroke CV death / nonfatal MI / stroke / refractory ischemia Secondary outcomes Severe or refractory ischemia Heart failure Need for revascularization
31 Key Inclusion Criteria Age 21 years Suspected UA or NSTEMI (no ST 1.0 mm) Presentation within 24 h after symptom onset ECG evidence of ischemia or elevated cardiac enzymes or troponin 2x ULN 1 CURE Study Protocol (Data on file, Sanofi-Synthelabo, Inc.) 2 CURE Study Investigators. Eur Heart J. 2000; 21:
32 Key Exclusion Criteria NYHA Class IV heart failure Uncontrolled hypertension At high risk for bleeding Eg. hemorrhagic stroke or intracranial hemorrhage Use of anticoagulants, clopidogrel, ticlopidine or NSAIDS Use of GP IIb/IIIa inhibitor within 3 days PCI or CABG within 3 months History of severe thrombocytopenia or neutropenia Contraindications to antithrombotics or antiplatelets
33 Overall Results: Efficacy Significant benefit to dual antiplatelets 20% RRR in primary outcome at mean of 9 months 9.3% vs 11.4%, p < Significant reductions in: In-hospital severe ischemia (RRR 26%) Recurrent angina (RRR 9%) Heart failure (RRR 18%)
34
35 Overall Results: Safety Significant 1% absolute increase in major bleeding with dual antiplatelet therapy 3.7% vs 2.7%, RR 1.38, p = Impact on life-threatening bleeding was not statistically significant 2.1% vs 1.8%, p = 0.13 No differences in thrombocytopenia or neutropenia
36 What were the results in patients undergoing CABG for NSTEMI?
37 CURE Surgical Revascularization Subgroup Analysis Circulation 2004; 110:
38 Study Population CURE patients PCI patients (21.2%) CABG 2072 patients (16.5%) Medical Therapy 7985 patients (62.3%) Placebo 1061 patients Clopidogrel 1011 patients No CABG patients were lost to follow-up 1928 of the CABG patients (93.0%) stopped the study drug before surgery 1451 of these patients (70.0%) resumed the study drug after surgery
39 Baseline Characteristics No significant differences between treatment arms Population Characteristics Male Hypertensive Smoker No previous revascularization ASA + UFH/LMWH No GP IIb/IIa Inh
40 Results: Primary Outcome Non-significant trend toward benefit in CABG subgroup CABG (Any Time) RR % CI Consistent with treatment effect observed in different therapy groups and overall CURE trial
41 Results: Primary Outcome Trend of greater benefit in those undergoing CABG during their initial hospitalization
42 Timing of Benefit Benefit driven by protection prior to CABG Overall - RR 0.89, 95% CI Pre-CABG - RR 0.82, 95% CI Post-CABG - RR 0.97, 95% CI Does this data imply anything regarding the potential benefit of continuing dual antiplatelet post-cabg? Benefit may be driven by acute protective effects associated with NSTEMI vs SVG disease Post-CABG benefit may be nominal Hypothesis-generating, but more research needed
43 Timing of Benefit Hypothesis: Benefit may be primarily associated with protection against acute effects of NSTEMI vs SVG disease
44 Results: Bleeding Post-operatively, operatively, strong trend towards: Major bleeding RR 1.27, 95% CI Life threatening bleeding RR 1.30, 95% CI
45 Results: Major Bleeding Non-significant trend towards increased major bleeding CABG (Any Time) RR % CI Trend of higher risk of bleeding than medical management
46 Risk of Bleeding Incidence (%) Major Bleeding After CABG Incidence (%) Life Threatening Bleeding After CABG Placebo Clopidogrel 0 Placebo Clopidogrel Post CABG Within 7 d Post CABG Within 7 d Post CABG: RR 1.3, 95% CI Within 7 d: RR 1.3, 95% CI Post CABG: RR 1.2, 95% CI Within 7 d: RR 1.3, 95% CI Majority of bleeds occurred within 7 d after CABG Non-significant trend towards increased bleeding with clopidogrel
47 Risk of Bleeding Effect of Discontinuation Time on Bleeding Risk Reduction (RR) Major Bleed Life Threatening Bleed <= 5 d > 5 NOTE: 95% CI for all comparison cross 1 Trend to increased major bleeding if clopidogrel stopped 5 d prior to CABG Trend to decreased bleeding if clopidogrel stopped > 5 d prior to CABG
48 Does the benefit outweigh the risk? Number of Events/1000 Patients Treated CV Death / Myocardial Infarction / Stroke 7 Bleeding Caused 4 LT Bleed Caused Events Pre-CABG
49 Does the benefit outweigh the risk? Number of Events/1000 Patients Treated CV Death / Myocardial Infarction / Stroke 17 Bleeding Caused Events Post-CABG 14 LT Bleed Caused Recall bleeding driven by acute post-operative bleeding complications with 7 d post-op
50 Does the benefit outweigh the risk? Benefit appears driven by pre-cabg outcomes Excess bleeding was limited to patients who discontinued clopidogrel within 5 d before CABG Risk is driven by pre-op decision to use clopidogrel Majority of major bleeds (67%) occurred within 7 days after CABG Median time to clopidogrel restart post-op op was 10 d
51 Does the benefit outweigh the risk? Benefit in CABG subgroup is relatively small and not significant
52 Study Strengths Intention-to to-treat treat analysis was performed Overall results in CABG subgroup were consistent with overall CURE population Impact of study drug was well-described Event rates for various discontinuation times documented
53 Study Limitations Data for patients proceeding to CABG is a post- hoc analysis Although results in this subgroup are consistent with the overall trial population, trial was not powered to show a treatment effect 75.3% of patients who stopped the study medication before surgery restarted it Further reduction power to show treatment effect In intention-to to-treat treat analysis, this would cause: Underestimate of treatment benefit Underestimate of bleeding risk
54 Study Limitations Protocol did not dictate timing of discontinuation of study drug pre-cabg Variable bleeding risk depending on timing! Protocol did not dictate timing of restart of study drug post-cabg Variable outcome depending on timing? Median time to restart was 10 days
55 What would you do? A) Start ASA alone 48 h post op B) Start ASA alone 10 d post op C) Start ASA + Clopidogrel 48 h post-op op D) Start ASA + Clopidogrel 10 d post-op op
56 Applying the Evidence to Your Patient Weigh risks and benefits of the following: Protection of functional stents Drug-eluting stents (DES) if < 1 year old Bare metal stents (BMS) if < 1 month old Antiplatelet therapy for NSTEMI Primary prevention of SVG disease Patient specific risk factors for bleeding
57 Application to Mr. R Risk of stent thrombosis of his unprotected DES was very high Post-operative operative bleeding complications were ruled out Clopidogrel was restarted 2 days post-op op
58 Application to Mr. R CURE data should be applied cautiously Mr. R would not have been a CURE patient given: Recent PCI < 3 months ago Use of GP IIb/IIIa IIIa inhibitor Use of clopidogrel pre-nstemi High risk of bleeding complications given his clopidogrel was continued until the time of CABG
59 Conclusions Using an EBM approach, All NSTEMI patients proceeding to CABG should receive dual antiplatelet therapy with ASA and clopidogrel for a duration up to 12 months Elective CABG should be delayed whenever possible to allow for clopidogrel to be discontinued for >5 days Wait days before restarting clopidogrel to minimize bleeding risk unless there is a compelling indication to restart earlier
60 Unresolved Questions Opportunity that the benefit of dual antiplatelet therapy post-cabg for NSTEMI can be refuted with further study If true benefit, What is the optimal time to restart? Does clopidogrel require a loading dose? Is there a difference between LIMA and SVG?
61 Future Study: CASCADE Prospective, randomized, double-blinded blinded placebo-controlled controlled trial Intervention Clopidogrel 75 mg/d + ASA 162 mg/d vs. ASA 162 mg/d alone 1 year duration starting on the day of surgery Patient population Patients undergoing multi-vessel elective or urgent CABG using at least 2 SVGs
62 Future Study: CASCADE Primary Outcome Reduction of vein graft intimal hyperplasia Secondary Outcomes Patency and stenosis as demonstrated by coronary and graft angiography Estimated Time of Completion November 2007
63 Discussion & Questions
Role of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationLearning Objectives. Epidemiology of Acute Coronary Syndrome
Cardiovascular Update: Antiplatelet therapy in acute coronary syndromes PHILLIP WEEKS, PHARM.D., BCPS-AQ CARDIOLOGY Learning Objectives Interpret guidelines as they relate to constructing an antiplatelet
More informationFastTest. You ve read the book now test yourself
FastTest You ve read the book...... now test yourself To ensure you have learned the key points that will improve your patient care, read the authors questions below. The answers will refer you back to
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationWhat oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor
76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class
More informationDECLARATION OF CONFLICT OF INTEREST. Lecture fees: AstraZeneca, Ely Lilly, Merck.
DECLARATION OF CONFLICT OF INTEREST Lecture fees: AstraZeneca, Ely Lilly, Merck. Risk of stopping dual therapy. S D Kristensen, FESC Aarhus Denmark Acute coronary syndrome: coronary thrombus Platelets
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationUpdate on Antithrombotic Therapy in Acute Coronary Syndrome
Update on Antithrombotic Therapy in Acute Coronary Syndrome Laura Tsang November 13, 2006 Objectives: By the end of this session, you should understand: The role of antithrombotics in ACS Their mechanisms
More informationBelinda Green, Cardiologist, SDHB, 2016
Acute Coronary syndromes All STEMI ALL Non STEMI Unstable angina Belinda Green, Cardiologist, SDHB, 2016 Thrombus in proximal LAD Underlying pathophysiology Be very afraid for your patient Wellens
More informationAcute Coronary Syndromes
Overview Acute Coronary Syndromes Rabeea Aboufakher, MD, FACC, FSCAI Section Chief of Cardiology Altru Health System Grand Forks, ND Epidemiology Pathophysiology Clinical features and diagnosis STEMI management
More informationTiming of Surgery After Percutaneous Coronary Intervention
Timing of Surgery After Percutaneous Coronary Intervention Deepak Talreja, MD, FACC Bayview/EVMS/Sentara Outline/Highlights Timing of elective surgery What to do with medications Stopping anti-platelet
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More information3/23/2017. Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate Europace Oct;14(10): Epub 2012 Aug 24.
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationAngelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017
Angelika Cyganska, PharmD Austin T. Wilson, MS, PharmD Candidate 2017 Explain the efficacy and safety of triple therapy, in regards to thromboembolic and bleeding risk Summarize the guideline recommendations
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationStephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland
Advances in Antiplatelet Therapy in PCI and ACS Stephan Windecker Department of Cardiology Swiss Cardiovascular Center and Clinical Trials Unit Bern Bern University Hospital, Switzerland Targets for Platelet
More informationCardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008.
Cardiovascular Health Nova Scotia Update to Antiplatelet Sections of the Nova Scotia Guidelines for Acute Coronary Syndromes, 2008. ST Elevation Myocardial Infarction (STEMI)-Acute Coronary Syndrome Guidelines:
More informationClopidogrel When For What For How Long. T Benjanuwattra Chiang Mai Heart Cent
Clopidogrel When For What For How Long T Benjanuwattra Chiang Mai Heart Cent Evidence Based Medicine I don t want to put you to sleep But want you to be fully alert Atherothrombosis: A Generalized and
More informationAn update on the management of UA / NSTEMI. Michael H. Crawford, MD
An update on the management of UA / NSTEMI Michael H. Crawford, MD New ACC/AHA Guidelines 2007 What s s new in the last 5 years CT imaging advances Ascendancy of troponin and BNP Clarification of ACEI/ARB
More informationCindy Stephens, MSN, ANP Kelly Walker, MS, ACNP Peter Cohn, MD, FACC
Cindy Stephens, MSN, ANP Kelly Walker, MS, ACNP Peter Cohn, MD, FACC Define Acute Coronary syndromes Explain the Cause Assessment, diagnosis and therapy Reperfusion for STEMI Complications to look for
More informationWhat is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation?
What is the Optimal Triple Anti-platelet Therapy Duration in Patients with Acute Myocardial Infarction Undergoing Drug-eluting Stents Implantation? Keun-Ho Park, Myung Ho Jeong, Min Goo Lee, Jum Suk Ko,
More informationAcute Coronary Syndrome. Sonny Achtchi, DO
Acute Coronary Syndrome Sonny Achtchi, DO Objectives Understand evidence based and practice based treatments for stabilization and initial management of ACS Become familiar with ACS risk stratification
More informationAdults With Diagnosed Diabetes
Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et
More informationSecondary Stroke Prevention: A Precautionary Tale
Secondary Stroke Prevention: A Precautionary Tale Kirsten George-Phillips, BSP Clinical Practice Leader, AHS Clinical Pharmacist, AHS Owen Stroke Prevention Clinic Learning Objectives! Examine literature
More informationLessons learned From The National PCI Registry
Lessons learned From The National PCI Registry w a v e On Behalf of The Publication Committee of the National PCI Registry Objectives & Anticipated Achievements To determine the epidemiology of patients
More information2/26/2013. NCDR.13 Case Scenario Presentation Cath PCI Registry. Disclosures. Objectives. Dashboard Implications of Some Major Metrics
NCDR.13 Case Scenario Presentation Cath PCI Registry Dashboard Implications of Some Major Metrics Disclosures Tony Hermann has nothing to disclose Mark Hutcheson has nothing to disclose Cornelia Anderson
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationComplicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital
Complicated issues in GI bleeding for internists? Nonthalee Pausawasdi, M.D. Faculty of Medicine Siriraj Hospital Complicated issues in GI bleeding; Survey results from internists Optimal resuscitation
More informationOUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.
OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral
More informationTiming of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC
Timing of Anti-Platelet Therapy for ACS (EARLY-ACS & ACUITY) Mitchell W. Krucoff, MD, FACC Professor, Medicine/Cardiology Duke University Medical Center Director, Cardiovascular Devices Unit Duke Clinical
More informationNon ST Elevation-ACS. Michael W. Cammarata, MD
Non ST Elevation-ACS Michael W. Cammarata, MD Case Presentation 65 year old man PMH: CAD s/p stent in 2008 HTN HLD Presents with chest pressure, substernally and radiating to the left arm and jaw, similar
More informationPrasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center
Prasugrel vs. Ticagrelor in ACS/PCI Which one to choose? V. Voudris MD FESC FACC 2 nd Cardiology Division Onassis Cardiac Surgery Center Hospitalizations in the U.S. Due to ACS Acute Coronary Syndromes
More informationClinical Case. Management of ACS Based on ACC/AHA & ESC Guidelines. Clinical Case 4/22/12. UA/NSTEMI: Definition
Clinical Case Management of ACS Based on ACC/AHA & ESC Guidelines Dr Badri Paudel Mr M 75M Poorly controlled diabetic Smoker Presented on Sat 7pm Intense burning in the retrosternal area Clinical Case
More informationObjectives. Treatment of ACS. Early Invasive Strategy. UA/NSTEMI General Concepts. UA/NSTEMI Initial Therapy/Antithrombotic
Objectives Treatment of ACS Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Define early invasive strategy and what patients typically receive this approach Compare/contrast the medications
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationOral Antiplatelet Therapy in PCI/ACS. Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine
Oral Antiplatelet Therapy in PCI/ACS Dominick J. Angiolillo, MD, PhD, FACC, FESC Director of Cardiovascular Research Assistant Professor of Medicine Basic Concepts Thrombus Formation Two key elements:
More informationAcute coronary syndromes
Acute coronary syndromes 1 Acute coronary syndromes Acute coronary syndromes results primarily from diminished myocardial blood flow secondary to an occlusive or partially occlusive coronary artery thrombus.
More informationSurgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome
Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures
More informationISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions
Julinda Mehilli, MD Deutsches Herzzentrum Technische Universität Munich Germany ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions Background Left main
More informationAcute Coronary Syndrome. ACC/AHA 2002 Guidelines
Acute Coronary Syndrome ACC/AHA 2002 Guidelines ACS Unstable Angina Non ST elevation MI ST elevation MI ACS UA and Non STEMI described in these guidelines Management of STEMI described in separate guidelines
More information1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES
1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)
More informationGRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017
GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional
More informationOptimal antiplatelet and anticoagulant therapy for patients treated in STEMI network
Torino 6 Joint meeting with Mayo Clinic Great Innovation in Cardiology 14-15 Ottobre 2010 Optimal antiplatelet and anticoagulant therapy for patients treated in STEMI network Diego Ardissino Ischemic vs
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More informationNova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines)
Cardiovascular Health Nova Scotia Guideline Update Nova Scotia Guidelines for Acute Coronary Syndromes (Updating the 2008 Antiplatelet Section of the Guidelines) Authors: Dr. M. Love, Dr. I. Bata, K. Harrigan
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Case Presentation 46 year old
More informationDiagnosis and Management of Acute Myocardial Infarction
Diagnosis and Management of Acute Myocardial Infarction Acute Myocardial Infarction (AMI) occurs as a result of prolonged myocardial ischemia Atherosclerosis leads to endothelial rupture or erosion that
More informationColumbia University Medical Center Cardiovascular Research Foundation
STEMI and NSTEMI Pharmacology Confusion: How to Choose and Use Antithrombins (Unfractionated and Low Molecular Heparins, Bivalirudin, Fondaparinux) and Antiplatelet Agents (Aspirin, Clopidogrel and Prasugrel)
More informationControversies in Cardiac Pharmacology
Controversies in Cardiac Pharmacology Thomas D. Conley, MD FACC FSCAI Disclosures I have no relevant relationships with commercial interests to disclose. 1 Doc, do I really need to take all these medicines?
More information2010, Metzler Helfried
Perioperative Strategies in Patients on Dual Antiplatelet Drug Therapy: Noncardiac Surgery H. Metzler Department of Anaesthesiology and Intensive Care Medicine Medical University of Graz, Austria What
More informationQuinn Capers, IV, MD
Heart Attacks Mended Hearts Presentation, January, 2017 Quinn Capers, IV, MD Associate Professor of Medicine (Cardiovascular Medicine) Director, Transradial Coronary Interventions Division of Cardiovascular
More informationSurveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management
Surveying the Landscape of Oral Antiplatelet Therapy in Acute Coronary Syndrome Management Jeffrey S Berger, MD, MS Assistant Professor of Medicine and Surgery Director of Cardiovascular Thrombosis Disclosures
More informationAcute Coronary Syndrome. Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine
Acute Coronary Syndrome Cindy Baker, MD FACC Director Peripheral Vascular Interventions Division of Cardiovascular Medicine Topics Timing is everything So many drugs to choose from What s a MINOCA? 2 Acute
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationCardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology
Cardiac evaluation for the noncardiac patient Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Objectives! Review ACC / AHA guidelines as updated for 2009! Discuss new recommendations
More informationST Elevation Myocardial Infarction
ST Elevation Myocardial Infarction Scott M. Lilly, MD, PhD Assistant Professor Clinical Department of Cardiovascular Medicine The Ohio State University Wexner Medical Center Outline Case Presentation STEMI
More information(ClinicalTrials.gov ID: NCT ) Title: The Italian Elderly ACS Study Author: Stefano Savonitto. Date: 29 August 2011 Meeting: ESC congress, Paris
Early aggressive versus initially conservative strategy in elderly patients with non-st- elevation acute coronary syndrome: the Italian randomised trial (ClinicalTrials.gov ID: NCT00510185) Stefano Savonitto,
More information8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None
Pre-op Evaluation for non cardiac surgery John Steuter, MD Disclosures None A quick review from 2007!! Fliesheret al, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and are for Noncardiac
More informationThe use of percutaneous coronary intervention (PCI) as
Antithrombotic Therapy During Percutaneous Coronary Intervention The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Jeffrey J. Popma, MD; Peter Berger, MD; E. Magnus Ohman, MD, FCCP;
More informationANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı
ANTITHROMBOTIC THERAPY 2010 Antitrombotik tedavi alan hastalarda operasyon hazırlığı Dr. Sabri DEMİRCAN Ondokuz Mayıs Üniversitesi Tıp Fakültesi Kardiyoloji ABD, Samsun Copyright 2001 Harcourt Canada Ltd.
More informationOptimal Duration and Dose of Antiplatelet Therapy after PCI
Optimal Duration and Dose of Antiplatelet Therapy after PCI Donghoon Choi, MD, PhD Severance Cardiovascular Center Yonsei University College of Medicine Optimal Duration of Antiplatelet Therapy after PCI
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationΔιάρκεια διπλής αντιαιμοπεταλιακής αγωγής. Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά
Διάρκεια διπλής αντιαιμοπεταλιακής αγωγής Νικόλαος Γ.Πατσουράκος Καρδιολόγος, Επιμελητής Α ΕΣΥ Τζάνειο Γενικό Νοσοκομείο Πειραιά International ACS guidelines: Recommendations on duration of dual
More informationNovel Anticoagulation Therapy in Acute Coronary Syndrome
Novel Anticoagulation Therapy in Acute Coronary Syndrome Soon Jun Hong Korea University Anam Hospital 1 Thrombus Formation Cascade Coagulation Cascade Platelet Cascade TXA2 Aspirin R Inhibitor Fondaparinux
More informationBivalirudin Clinical Trials Update Evidence and Future Perspectives
Bivalirudin Clinical Trials Update Evidence and Future Perspectives Andreas Baumbach Consultant Cardiologist/ hon. Reader in Cardiology Bristol Heart Institute University Hospitals Bristol MY CONFLICTS
More informationRecombinant Factor VIIa for Intracerebral Hemorrhage
Recombinant Factor VIIa for Intracerebral Hemorrhage January 24, 2006 Justin Lee Pharmacy Resident University Health Network Outline 1. Introduction to patient case 2. Overview of intracerebral hemorrhage
More informationA Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS
A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators
More informationDisclosures. Inpatient Management of Non-ST Elevation Acute Coronary Syndromes. Edward McNulty MD, FACC. None
Inpatient Management of Non-ST Elevation Acute Coronary Syndromes Edward McNulty MD, FACC Assistant Clinical Professor UCSF Director, SF VAMC Cardiac Catheterization Laboratory Disclosures None New Guidelines
More informationCOAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY
COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET
More informationThe Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial
Benefits and Risks of the Combination of Clopidogrel and Aspirin in Patients Undergoing Surgical Revascularization for Non ST-Elevation Acute Coronary Syndrome The Clopidogrel in Unstable angina to prevent
More informationObjectives. Acute Coronary Syndromes; The Nuts and Bolts. Overview. Quick quiz.. How dose the plaque start?
Objectives Acute Coronary Syndromes; The Nuts and Bolts Michael P. Gulseth, Pharm. D., BCPS Pharmacotherapy II Spring 2006 Compare and contrast pathophysiology of unstable angina (UA), non-st segment elevation
More informationDIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN
DIFFERENTIATING THE PATIENT WITH UNDIFFERENTIATED CHEST PAIN Objectives Gain competence in evaluating chest pain Recognize features of moderate risk unstable angina Review initial management of UA and
More informationDISCLOSURE. What I am Talking About. Rational Use of Antiplatelet Agents. Aspirin. Tom DeLoughery, MD MACP FAWM
Rational Use of Antiplatelet Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Tom DeLoughery, MD MACP FAWM Oregon Health and Sciences University What I am Talking About 1. Current
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More informationAPPENDIX F: CASE REPORT FORM
APPENDIX F: CASE REPORT FORM Instruction: Complete this form to notify all ACS admissions at your centre to National Cardiovascular Disease Registry. Where check boxes are provided, check ( ) one or more
More informationTicagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
More informationAntiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants
Antiplatelet Therapy: Current Recommendations for Choice of Agent and Concurrent Therapy with Warfarin and Novel Oral Anticoagulants S. Hinan Ahmed, MD Anti-platelet Therapy: Simple Answer Bare metal stent
More informationSheffield guidelines for the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017)
Sheffield guidelines f the use of antiplatelets in the prevention and treatment of cardiovascular disease (October 2017) Approved by Sheffield Area Prescribing Committee and Sheffield Teaching Hospitals
More informationPerioperative Management of the Surgical Patient with a Drug-Eluting Stent. Objectives
Perioperative Management of the Surgical Patient with a Drug-Eluting Stent Calvin Au MD Division of Cardiac Anesthesia Vancouver General Hospital Objectives Review the history of Drug Eluting Stents (DES)
More informationPrevention of Coronary Stent Thrombosis and Restenosis
Prevention of Coronary Stent Thrombosis and Restenosis Seong-Wook Park, MD, PhD, FACC Division of Cardiology, Asan Medical Center University of Ulsan College of Medicine, Seoul, Korea 9/12/03 Coronary
More informationSTEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology
STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationMINERVA MEDICA COPYRIGHT. Aspirin is accepted as standard antiplatelet. Dual antiplatelet therapy for primary and secondary prevention
This document is protected by international copyright laws. No additional reproduction is authorized. It is permitted for personal use to download and save only one file and print only one copy of this
More informationPathology of percutaneous interventions (PCI) in coronary arteries. Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL
Pathology of percutaneous interventions (PCI) in coronary arteries Allard van der Wal, MD.PhD; Pathologie AMC, Amsterdam, NL Percutaneous Coronary Intervention (PCI) Definition: transcatheter opening of
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More information- May Help Increase Appropriate Early Use in Acute Coronary Syndrome Patients -
MEDIA INVESTORS Ken Dominski John Elicker Bristol-Myers Squibb Bristol-Myers Squibb 609-252-5251 212-546-3775 ken.dominski@bms.com john.elicker@bms.com Amy Ba Felix Lauscher sanofi-aventis sanofi-aventis
More informationCPORT E Trial. Atlantic C PORT
CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program
More informationTRIAS HR Pilot Study
Late Breaking Clinical Trials TCT, October 22 nd 27, Washington, USA TRIAS HR Pilot Study RCT comparing Genous EPC capturing stent with Taxus Paclitaxel eluting stent Robbert J de Winter MD PhD FESC Academic
More informationCardiovascular Concerns in Intermediate Care
Cardiovascular Concerns in Intermediate Care GINA ST. JEAN RN, MSN, CCRN-CSC CLINICAL NURSE EDUCATOR HEART AND & CRITICAL AND INTERMEDIATE CARE Objectives: Identify how to do a thorough assessment of the
More informationAnti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib!
Anti-platelet Therapies in Cardiovascular Disease: From Stable CAD to ACS and Afib! Roxana Mehran, MD Columbia University Medical Center Cardiovascular Research Foundation Disclosures Research support
More informationAbciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial
Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.
More informationPercutaneous Coronary Interventions Without On-site Cardiac Surgery
Percutaneous Coronary Interventions Without On-site Cardiac Surgery Hassan Al Zammar, MD,FESC Consultant & Interventional Cardiologist Head of Cardiology Department European Gaza Hospital Palestine European
More informationDental Management Considerations for Patients on Antithrombotic Therapy
Dental Management Considerations for Patients on Antithrombotic Therapy Warfarin and Antiplatelet Joel J. Napeñas DDS FDSRCS(Ed) Program Director General Practice Residency Program Department of Oral Medicine
More informationCABG Surgery following STEMI
CABG Surgery following STEMI Susana Harrington, MS,APRN-NP Cardio-Thoracic Surgery Nebraska Methodist Hospital February 15, 2018 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction:
More informationMyocardial Infarction In Dr.Yahya Kiwan
Myocardial Infarction In 2007 Dr.Yahya Kiwan New Definition Of Acute Myocardial Infarction The term of myocardial infarction should be used when there is evidence of myocardial necrosis in a clinical setting
More informationChest pain and troponins on the acute take. J N Townend Queen Elizabeth Hospital Birmingham
Chest pain and troponins on the acute take J N Townend Queen Elizabeth Hospital Birmingham 3 rd Universal Definition of Myocardial Infarction Type 1: Spontaneous MI related to atherosclerotic plaque rupture
More informationDual Antiplatelet Therapy Made Practical
Dual Antiplatelet Therapy Made Practical David Parra, Pharm.D., FCCP, BCPS Clinical Pharmacy Program Manager in Cardiology/Anticoagulation VISN 8 Pharmacy Benefits Management Clinical Associate Professor
More information